Fulvestrant: benefits at acceptable costs in advanced breast cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.571, 2009-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer

By Robertson J.F.R.

Clinical Pharmacokinetics, Vol. 43, Iss. 8, 2004-01 ,pp. : 529-538

Adis International

Access to resources Recommend Favorite

Fulvestrant as EFECTive as exemestane in advanced breast cancer

Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Fulvestrant – a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer

By Possinger Kurt

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2549-2558

Informa Healthcare

Access to resources Recommend Favorite

Fulvestrant looks on track to fulfil expectations in advanced breast cancer

Inpharma, Vol. 1, Iss. 1315, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer

By Scott Sarah M Brown Myles Come Steven E

Expert Opinion on Drug Safety, Vol. 10, Iss. 5, 2011-09 ,pp. : 819-826

Informa Healthcare

Access to resources Recommend Favorite